Table 1.
Clinicopathological features of the study cohort
| Parameters | Cohort | VAT% < 31.89 % | VAT% ≥ 31.89 % | P value |
|---|---|---|---|---|
| N = 200 | N = 100 | N = 100 | ||
| Median age (range), years | 54 (28–84) | 52 (28–82) | 57 (34–84) | <0.001 a |
| Premenopausal patients (%) | 83 (41.5 %) | 52 (52.0 %) | 31 (31.0 %) | 0.003 b |
| Hypertension (%) | 57 (28.5 %) | 19 (19.0 %) | 38 (38.0 %) | 0.003 b |
| Diabetes (%) | 27 (13.5 %) | 9 (9.0 %) | 18 (18.0 %) | 0.063b |
| Positive peritoneal cytology (%) | 16 (9.4 %) n = 171 | 10 (11.6 %) n = 86 | 6 (7.1 %) n = 85 | 0.305b |
| Histology | ||||
| Endometrioid (%) | 181 (90.5 %) | 92 (92.0 %) | 89 (89.0 %) | 0.381c |
| Serous (%) | 13 (6.5 %) | 4 (4.0 %) | 9 (9.0 %) | |
| Clear cell (%) | 4 (2.0 %) | 3 (3.0 %) | 1 (1.0 %) | |
| Mucinous (%) | 2 (1.0 %) | 1 (1.0 %) | 1 (1.0 %) | |
| Histological grade | ||||
| Grade 1 | 86 (43.0 %) | 48 (48.0 %) | 38 (38.0 %) | 0.069b |
| Grade 2 | 85 (42.5 %) | 43 (43.0 %) | 42 (42.0 %) | |
| Grade 3 | 29 (14.5 %) | 9 (9.0 %) | 20 (20.0 %) | |
| Deep myometrial invasion (≥50 %) (%) | 46 (23.0 %) | 18 (18.0 %) | 28 (28.0 %) | 0.093b |
| Average tumor size (range), cm | 3.14 (0.2–20) | 3.19 (0.3–12) | 3.09 (0.2–20) | 0.791a |
| n = 165d | n = 84d | n = 81d | ||
| LN metastasis | 22 (11.0 %) | 6 (6.0 %) | 16 (16.0 %) | 0.024 b |
| Median No. retrieved LNs (range) | 25 (4–56) | 26 (4–55) | 24 (4–56) | 0.160a |
| Lympho-vascular invasion (%) | 37 (19.9 %) n = 186 | 17 (18.3 %) n = 93 | 20 (21.5 %) n = 93 | 0.582b |
| Extrauterine disease (%) | 28 (14.0 %) | 9 (9.0 %) | 19 (19.0 %) | 0.042 b |
| FIGO stage | ||||
| IA (%) | 134 (67.0 %) | 73 (73.0 %) | 61 (61.0 %) | |
| IB (%) | 23 (11.5 %) | 11 (11.0 %) | 12 (12.0 %) | |
| II (%) | 15 (7.5 %) | 7 (7.0 %) | 8 (8.0 %) | |
| IIIA (%) | 3 (1.5 %) | 2 (2.0 %) | 1 (1.0 %) | |
| IIIB (%) | 2 (1.0 %) | 1 (1.0 %) | 1 (1.0 %) | |
| IIIC (%) | 23 (11.5 %) | 6 (6.0 %) | 17 (17.0 %) | |
| Median BMI (range), kg/m2 | 24.7 (17.5–43.7) | 24.6 (18.03–43.7) | 24.83 (17.53–35.16) | 0.280a |
| Median VAT (range), mm2 | 17338 (5990–37118) | 13780 (5990–31708) | 20187(6649–37188) | <0.001 a |
| Median SAT (range), mm2 | 35607 (10458–106902) | 41395 (20347–106902) | 30360 (10458–61074) | <0.001 a |
| Median VAT% (range) | 31.89 (13.97–59.57) | 25.99 (13.97–31.88) | 38.78(31.90–59.57) | <0.001 a |
aStudent’s T test
bPearson Chi-square test
cLikelihood ratio
dNot all patients have tumor size recorded in the pathology report. Tumor confined within endometrium was reported without tumor size in 14 cases (7 and 7 in high and low VAT% group, respectively). A total of 21 patients (9 and 12 in high and low VAT% group, respectively) did not have tumor lesion in the final pathology after dilation and curettage
Abbreviations: LN lymph node, BMI body mass index, SAT subcutaneous Adipose Tissue, VAT visceral adipose tissue, VAT % percentage of visceral adipose tissue
Bold value denotes P with statistical significance